BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a large decrease in short interest during the month of July. As of July 15th, there was short interest totalling 29,400 shares, a decrease of 38.8% from the June 30th total of 48,000 shares. Based on an average daily trading volume, of 150,600 shares, the short-interest ratio is presently 0.2 days. Approximately 2.3% of the shares of the company are short sold.

BioCardia Stock Up 1.4 %

Shares of NASDAQ BCDA traded up $0.04 during trading on Friday, reaching $2.99. 19,967 shares of the stock traded hands, compared to its average volume of 77,107. BioCardia has a 52-week low of $2.62 and a 52-week high of $23.25. The company has a 50-day moving average of $3.66 and a 200-day moving average of $5.49.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($1.35) EPS for the quarter. The firm had revenue of $0.06 million for the quarter. BioCardia had a negative net margin of 2,208.76% and a negative return on equity of 3,638.68%. During the same quarter in the previous year, the company earned ($2.55) earnings per share. On average, equities research analysts anticipate that BioCardia will post -6.3 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of BioCardia in a research report on Friday.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.